SCI Pharmtech Inc Market Cap ($192.02 Million)
Market Cap & Net Worth: SCI Pharmtech Inc (4119)
SCI Pharmtech Inc market cap. SCI Pharmtech Inc (TW:4119) has a market capitalization of $192.02 Million (NT$6.09 Billion) as of November 1, 2026. Listed on the TW stock exchange, this Taiwan-based company holds position #16507 globally and #805 in its home market, demonstrating a -4.49% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SCI Pharmtech Inc's stock price NT$51.00 by its total outstanding shares 119508634 (119.51 Million). Also see cash efficiency ratio of SCI Pharmtech Inc for how efficiently the company converts equity into cash flow.
SCI Pharmtech Inc Market Cap History (2015–2026)
SCI Pharmtech Inc market cap history from 2015 to 2026. Data shows change from $295.31 Million to $192.02 Million (-2.38% CAGR). Check 4119 stock price for real-time trading data and today's change.
SCI Pharmtech Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SCI Pharmtech Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore SCI Pharmtech Inc (4119) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.14x
SCI Pharmtech Inc's market cap is 0.14 times its annual revenue
Latest Price to Earnings (P/E) Ratio
1.71x
SCI Pharmtech Inc's market cap is 1.71 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $250.50 Million | $1.90 Billion | $416.95 Million | 0.13x | 0.60x |
| 2017 | $197.39 Million | $1.30 Billion | $190.98 Million | 0.15x | 1.03x |
| 2018 | $248.43 Million | $1.94 Billion | $447.24 Million | 0.13x | 0.56x |
| 2019 | $394.43 Million | $2.36 Billion | $571.10 Million | 0.17x | 0.69x |
| 2020 | $314.07 Million | $2.69 Billion | $360.12 Million | 0.12x | 0.87x |
| 2021 | $315.59 Million | $864.22 Million | $55.70 Million | 0.37x | 5.67x |
| 2022 | $366.31 Million | $899.74 Million | $308.78 Million | 0.41x | 1.19x |
| 2023 | $364.47 Million | $1.20 Billion | $294.72 Million | 0.30x | 1.24x |
| 2024 | $341.13 Million | $1.52 Billion | $534.68 Million | 0.22x | 0.64x |
| 2025 | $183.36 Million | $1.34 Billion | $107.37 Million | 0.14x | 1.71x |
Competitor Companies of 4119 by Market Capitalization
Companies near SCI Pharmtech Inc in the global market cap rankings as of November 1, 2026. Also see SCI Pharmtech Inc assets under control for a full breakdown of the balance sheet.
Key companies related to SCI Pharmtech Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #535 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.62 |
| #593 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of SCI Pharmtech Inc (2015–2026)
Market capitalization of SCI Pharmtech Inc from 2015 to today. Between 2015 and today, SCI Pharmtech Inc's market cap moved from $295.31 Million to $ 192.02 Million, with a yearly change of -2.38%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$192.02 Million | +4.72% |
| 2025 | NT$183.36 Million | -46.25% |
| 2024 | NT$341.13 Million | -6.40% |
| 2023 | NT$364.47 Million | -0.50% |
| 2022 | NT$366.31 Million | +16.07% |
| 2021 | NT$315.59 Million | +0.48% |
| 2020 | NT$314.07 Million | -20.37% |
| 2019 | NT$394.43 Million | +58.77% |
| 2018 | NT$248.43 Million | +25.86% |
| 2017 | NT$197.39 Million | -21.20% |
| 2016 | NT$250.50 Million | -15.18% |
| 2015 | NT$295.31 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of SCI Pharmtech Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $192.02 Million USD |
| MoneyControl | $192.02 Million USD |
| MarketWatch | $192.02 Million USD |
| marketcap.company | $192.02 Million USD |
| Reuters | $192.02 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About SCI Pharmtech Inc
SCI Pharmtech, Inc. engages in the research and development, manufacture, and sale of active pharmaceutical ingredients, intermediates, and specialty chemicals. The company offers active pharmaceutical ingredients, including adenine, articaine HCl, atomoxetine HCl, bisoprolol hemifumarate, brinzolamide, buprenorphine and buprenorphine HCl, cannabidol, divalproex sodium, duloxetine HCl, hydroxychl… Read more